A phase II, randomized, double-blind, placebo-controlled study of simtuzumab in combination with FOLFIRI for the Second-Line treatment of metastatic KRAS mutant colorectal adenocarcinoma

J. Randolph Hecht, Al B. Benson, Dmitry Vyushkov, Yingsi Yang, Johanna Bendell, Udit Verma